Literature DB >> 29520722

Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.

Mohammad Javad Ebrahimi1, Abbas Aliaghaei1, Mahdi Eskandarian Boroujeni2, Fariba Khodagholi3, Gholamhoussein Meftahi4, Mohammad Amin Abdollahifar1, Houssein Ahmadi1, Samira Danyali5, Mahtab Daftari3, Yousef Sadeghi6.   

Abstract

Huntington disease (HD) is an inherited disorder hallmarked by progressive deterioration of specific neurons, followed by movement and cognitive anomalies. Cell therapy approaches in neurodegenerative conditions have concentrated on the replenishment of lost/dying neurons with functional ones. Multipotent mesenchymal stem cells (MSCs) have been represented as a potential remedy for HD. In this study, we evaluated the in vitro and in vivo efficacy of umbilical cord matrix stem cells (UCMSCs) and their paracrine effect against oxidative stress with a specific focus on HD. To this end, UCMSCs were isolated, immunophenotypically characterized by the positive expression of MSC markers, and exhibited multilineage potentiality. Besides, synthesis of neurotrophic factors of GDNF and VEGF by UCMSC was confirmed. Initially, PC12 cells were exposed to superoxide in the presence of conditioned media (CM) collected from UCMSC (UCMSC-CM) and cell viability plus neuritogenesis were measured. Next, bilateral striatal transplantation of UCMSC in 3-nitropropionic acid (3-NP) lesioned rat models was conducted, and 1 month later, post-graft analysis was performed. According to our in vitro results, CM of UCMSC protected PC12 cells against oxidative stress and considerably enhanced cell viability and neurite outgrowth. On the other hand, transplanted UCMSC survived, decreased gliosis, and ameliorated motor coordination and muscle activity, along with an increase in striatal volume as well as in dendritic length of the striatum in HD rats. Collectively, our findings imply that UCMSCs provide an enriched platform by largely their paracrine factors, which downgrades the unfavorable effects of oxidative stress.

Entities:  

Keywords:  Cell therapy; Huntington disease; Mesenchymal stem cells; Umbilical cord

Mesh:

Substances:

Year:  2018        PMID: 29520722     DOI: 10.1007/s12640-018-9884-4

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  36 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  Structural and functional characterization of HLA-DR molecules circulating in the serum.

Authors:  M Jendro; J J Goronzy; C M Weyand
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

Review 3.  Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord.

Authors:  Cun-Gang Fan; Qing-jun Zhang; Jing-ru Zhou
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

4.  Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum.

Authors:  Stuart M Ellison; Antonio Trabalza; Veronica Tisato; Evangelos Pazarentzos; Shirley Lee; Vasiliki Papadaki; Despoina Goniotaki; Sarah Morgan; Nazanin Mirzaei; Nicholas D Mazarakis
Journal:  Mol Ther       Date:  2013-06-25       Impact factor: 11.454

5.  Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease.

Authors:  Nicholas D Dey; Matthew C Bombard; Bartholomew P Roland; Stacy Davidson; Ming Lu; Julien Rossignol; Michael I Sandstrom; Reid L Skeel; Laurent Lescaudron; Gary L Dunbar
Journal:  Behav Brain Res       Date:  2010-05-21       Impact factor: 3.332

Review 6.  Cell therapy in Huntington disease.

Authors:  Claire D Clelland; Roger A Barker; Colin Watts
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

7.  Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease.

Authors:  Kadiombo Bantubungi; David Blum; Laetitia Cuvelier; Sabine Wislet-Gendebien; Bernard Rogister; Emmanuel Brouillet; Serge N Schiffmann
Journal:  Mol Cell Neurosci       Date:  2007-11-12       Impact factor: 4.314

8.  Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis.

Authors:  Kyle D Fink; Julien Rossignol; Andrew T Crane; Kendra K Davis; Matthew C Bombard; Angela M Bavar; Steven Clerc; Steven A Lowrance; Cheng Song; Laurent Lescaudron; Gary L Dunbar
Journal:  Stem Cell Res Ther       Date:  2013-10-24       Impact factor: 6.832

9.  Islet-like clusters derived from mesenchymal stem cells in Wharton's Jelly of the human umbilical cord for transplantation to control type 1 diabetes.

Authors:  Kuo Ching Chao; Kuo Fang Chao; Yu Show Fu; Shing Hwa Liu
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240

Review 10.  Umbilical cord: an unlimited source of cells differentiable towards dopaminergic neurons.

Authors:  Mahdi Eskandarian Boroujeni; Mossa Gardaneh
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

View more
  7 in total

Review 1.  Applying stem cell therapy in intractable diseases: a narrative review of decades of progress and challenges.

Authors:  Anna Pick Kiong Brianna; Ying Pei Ling
Journal:  Stem Cell Investig       Date:  2022-09-30

Review 2.  Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects.

Authors:  Mohaddeseh Rahbaran; Angelina Olegovna Zekiy; Mahta Bahramali; Mohammadsaleh Jahangir; Mahsa Mardasi; Delaram Sakhaei; Lakshmi Thangavelu; Navid Shomali; Majid Zamani; Ali Mohammadi; Negin Rahnama
Journal:  Cell Mol Biol Lett       Date:  2022-07-16       Impact factor: 8.702

Review 3.  Current and Possible Future Therapeutic Options for Huntington's Disease.

Authors:  Mackenzie W Ferguson; Connor J Kennedy; Thulani H Palpagama; Henry J Waldvogel; Richard L M Faull; Andrea Kwakowsky
Journal:  J Cent Nerv Syst Dis       Date:  2022-05-21

Review 4.  Prion-like mechanisms in neurodegenerative disease: Implications for Huntington's disease therapy.

Authors:  Bhairavi Srinageshwar; Robert B Petersen; Gary L Dunbar; Julien Rossignol
Journal:  Stem Cells Transl Med       Date:  2020-01-30       Impact factor: 6.940

Review 5.  Human Umbilical Cord Mesenchymal Stem Cells: Current Literature and Role in Periodontal Regeneration.

Authors:  Muhammad Saad Shaikh; Zara Shahzad; Esraa Abdulgader Tash; Omer Sefvan Janjua; Muhammad Ikram Khan; Muhammad Sohail Zafar
Journal:  Cells       Date:  2022-03-30       Impact factor: 6.600

Review 6.  Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach.

Authors:  Hadi Yari; Maria V Mikhailova; Mahsa Mardasi; Mohsen Jafarzadehgharehziaaddin; Somayeh Shahrokh; Lakshmi Thangavelu; Hosein Ahmadi; Navid Shomali; Yoda Yaghoubi; Majid Zamani; Morteza Akbari; Samira Alesaeidi
Journal:  Stem Cell Res Ther       Date:  2022-08-19       Impact factor: 8.079

Review 7.  Therapeutic Strategies in Huntington's Disease: From Genetic Defect to Gene Therapy.

Authors:  Anamaria Jurcau; Maria Carolina Jurcau
Journal:  Biomedicines       Date:  2022-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.